Bartee Mee Y, Dunlap Katherine M, Bartee Eric
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC.
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC.
Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):203-12. doi: 10.1016/j.clml.2015.12.005. Epub 2015 Dec 23.
Multiple myeloma is a clonal malignancy of plasma B cells. Although recent advances have improved overall prognosis, virtually all myeloma patients still succumb to relapsing disease. Therefore, novel therapies to treat this disease remain urgently needed. We have recently shown that treatment of human multiple myeloma cells with an oncolytic virus known as myxoma results in rapid cell death even in the absence of viral replication; however, the specific mechanisms and pathways involved remain unknown.
To determine how myxoma virus eliminates human multiple myeloma cells, we queried the apoptotic pathways that were activated after viral infection using immunoblot analysis and other cell biology approaches.
Our results indicate that myxoma virus infection initiates apoptosis in multiple myeloma cells through activation of the extrinsic initiator caspase-8. Caspase-8 activation subsequently results in cleavage of BH3 interacting-domain death agonist and loss of mitochondrial membrane potential causing secondary activation of caspase-9. Activation of caspase-8 appears to be independent of extrinsic death ligands and instead correlates with depletion of cellular inhibitors of apoptosis. We hypothesize that this depletion results from virally mediated host-protein shutoff because a myxoma construct that overexpresses the viral decapping enzymes displays improved oncolytic potential.
Taken together, these results suggest that myxoma virus eliminates human multiple myeloma cells through a pathway unique to oncolytic poxviruses, making it an excellent therapeutic option for the treatment of relapsed or refractory patients.
多发性骨髓瘤是浆细胞B的克隆性恶性肿瘤。尽管最近的进展改善了总体预后,但几乎所有骨髓瘤患者最终仍死于疾病复发。因此,治疗这种疾病的新疗法仍迫切需要。我们最近发现,用一种称为黏液瘤的溶瘤病毒治疗人类多发性骨髓瘤细胞,即使在没有病毒复制的情况下也会导致细胞迅速死亡;然而,具体涉及的机制和途径仍不清楚。
为了确定黏液瘤病毒如何消除人类多发性骨髓瘤细胞,我们使用免疫印迹分析和其他细胞生物学方法,探究了病毒感染后激活的凋亡途径。
我们的结果表明,黏液瘤病毒感染通过激活外源性起始半胱天冬酶-8在多发性骨髓瘤细胞中引发凋亡。半胱天冬酶-8的激活随后导致BH3相互作用结构域死亡激动剂的裂解以及线粒体膜电位的丧失,从而引起半胱天冬酶-9的二次激活。半胱天冬酶-8的激活似乎独立于外源性死亡配体,而是与细胞凋亡抑制剂的耗竭相关。我们推测这种耗竭是由病毒介导的宿主蛋白关闭引起的,因为过表达病毒脱帽酶的黏液瘤构建体显示出更好的溶瘤潜力。
综上所述,这些结果表明黏液瘤病毒通过溶瘤痘病毒特有的途径消除人类多发性骨髓瘤细胞,使其成为治疗复发或难治性患者的极佳治疗选择。